Antiplatelet Effects of Selected Xanthine-Based Adenosine A2A and A2B Receptor Antagonists Determined in Rat Blood

Int J Mol Sci. 2023 Aug 29;24(17):13378. doi: 10.3390/ijms241713378.

Abstract

The platelet aggregation inhibitory activity of selected xanthine-based adenosine A2A and A2B receptor antagonists was investigated, and attempts were made to explain the observed effects. The selective A2B receptor antagonist PSB-603 and the A2A receptor antagonist TB-42 inhibited platelet aggregation induced by collagen or ADP. In addition to adenosine receptor blockade, the compounds were found to act as moderately potent non-selective inhibitors of phosphodiesterases (PDEs). TB-42 showed the highest inhibitory activity against PDE3A along with moderate activity against PDE2A and PDE5A. The antiplatelet activity of PSB-603 and TB-42 may be due to inhibition of PDEs, which induces an increase in cAMP and/or cGMP concentrations in platelets. The xanthine-based adenosine receptor antagonists were found to be non-cytotoxic for platelets. Some of the compounds showed anti-oxidative properties reducing lipid peroxidation. These results may provide a basis for the future development of multi-target xanthine derivatives for the treatment of inflammation and atherosclerosis and the prevention of heart infarction and stroke.

Keywords: A2B receptor antagonists; A2B receptors; adenosine A2A; anti-aggregation effect; antiplatelet activity; lipid peroxidation; phosphodiesterase activity.

MeSH terms

  • Adenosine
  • Animals
  • Atherosclerosis*
  • Blood Platelets*
  • Rats
  • Xanthine / pharmacology

Substances

  • Xanthine
  • diethylstilbestrol monophosphate
  • Adenosine